Business Wire

PQE Group Joins Project-COMFORT to Advance Patient-Centric Blood Collection and Diagnostics

Share

PQE Group, a global consulting firm specializing in Life Sciences, is proud to contribute its expertise as a strategic partner in the Project-COMFORT consortium. This innovative public-private partnership, funded by Horizon Europe and supported by the Innovative Health Initiative Joint Undertaking (IHI JU), officially launched in November 2024, marking a transformative shift in blood collection and diagnostics. The ambitious 42-month project brings together 51 organizations from a broad spectrum of sectors, including academia, research institutions, hospitals, foundations, SMEs, medical technology, and pharmaceutical companies, all united by the mission to simplify, reduce the invasiveness of, and increase accessibility to blood collection through cutting-edge, patient-centered microsampling technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241229266268/en/

Follow Project-Comfort LinkedIn Page: https://www.linkedin.com/company/project-comfort (Graphic: Business Wire)

“We are proud to collaborate on this groundbreaking project, which perfectly aligns with our commitment to advancing healthcare solutions that prioritize patients,” said Luca Zanotti Fragonara, Advanced Technologies Competence Center Lead at PQE Group. “Together with our partners, we aim to make blood collection and diagnostics more accessible, comfortable, and efficient, ultimately improving health outcomes globally.”

On behalf of the consortium, Project Leader Antoniu L. Fantana, PhD, Sr. Director, Eli Lilly and Company stated: “Our goal is to redefine diagnostics by placing patient needs at the forefront and expanding healthcare access globally. Together with 51 dedicated organizations, we are committed to establishing a new standard in blood collection and diagnostics that combines patient comfort and accessibility with higher quality data.”

Traditional blood collection methods, such as venipuncture, can be burdensome and uncomfortable, particularly for patients with limited mobility, children, the elderly, and those in rural or underserved areas. The need to visit a clinical setting often poses additional challenges, including time, cost, and travel barriers. Project-COMFORT addresses these obstacles head-on by advancing Patient-Centric Microsampling — an approach allowing smaller blood samples to be collected comfortably at home or in other convenient locations. This shift will greatly enhance diagnostic accessibility, reduce patient discomfort, and make timely health monitoring a reality for those who need it most.

“By offering a minimally invasive, patient-friendly alternative, microsampling represents a major step forward in democratizing healthcare access,” noted Scientific Coordinator Chi Pakarinen. “Our project is about breaking down barriers to care and reimagining blood diagnostics as an inclusive, adaptable service that meets patients where they are.”

Project-COMFORT leverages the diverse expertise of its partners, blending insights from healthcare providers, research institutions, patient advocacy groups, and technology innovators. The aim is to also involve regulatory and HTA experts from the start to ensure the best chances for successful project implementation and better uptake of project results. This unique collaboration integrates advanced clinical research, regulatory compliance, and technological development, creating a robust foundation for microsampling to emerge as a recognized standard. With expertise spanning a broad array of disciplines, the consortium partners are collectively building a model that can lead to more patient-centered, efficient healthcare in the future.

“At the heart of Project-COMFORT is a commitment to patient-centered innovation,” said Administrative Coordinator Professor Georgios Theodoridis, School of Chemistry, Aristotle University of Thessaloniki. “This project holds groundbreaking potential to make Patient-Centric Microsampling an accepted alternative to traditional blood draws, fundamentally transforming the diagnostic experience for patients. By reducing the burden of testing and enhancing accessibility, we are paving the way for data-driven healthcare advancements that will improve patient outcomes and support more effective healthcare planning worldwide.”

The project’s ultimate goal is to generate impactful, data-driven insights that not only improve individual patient care but also guide public health strategies. The rich data made available through microsampling technology has the potential to influence healthcare policy, resource allocation, and preventive care measures, leading to a healthier, more resilient population.

With this launch, Project-COMFORT embarks on a journey of global impact, backed by €6,6 million in funding and an unparalleled commitment from its diverse network of partners. By engaging patient communities, healthcare providers, and regulatory bodies from the outset, the project will ensure that each stage of development is attuned to real-world needs and expectations. As Project-COMFORT progresses, regular updates and collaboration opportunities will be shared to welcome stakeholders into this groundbreaking healthcare transformation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241229266268/en/

Contacts

Media Contact:
Michela Lijoi – m.lijoi@pqegroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Perma-Pipe International Holdings, Inc. Announces $43 Million Contract Award in the Middle East Region10.1.2025 16:23:00 EET | Press release

Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH) today announced it has received a formal letter of award for a development project located in the GCC region. Perma-Pipe will provide thermal insulation, anti-corrosion coatings, and other services from its Abu Dhabi facility. Project commencement is expected to begin in the third quarter of 2025. The value of this project is estimated to exceed $43 million. This project will utilize Perma-Pipe’s anti-corrosion coatings capabilities, fabrication, and the TRACE-THERM® insulation system, a spray-applied polyurethane foam jacketed with a high-density polyethylene casing. Saleh Sagr, Sr. Vice President for Perma-Pipe’s MENA region, commented, “This award follows the successful execution of numerous development projects in the region. Our differentiated coating solutions have proven to be well-suited for technically challenging projects. We would like to thank our customers for this significant award.” David Mansfield, President and CEO

Lenovo Integrates AI and Robotics to Deliver Smarter Retail Solutions10.1.2025 16:00:00 EET | Press release

Lenovo today introduced three new retail solutions that combine the best of robotics and artificial intelligence technologies. Premiering at NRF 2025 in New York City, each solution has been field-tested and proven in commercial settings. Lenovo Retail Content Management Services enables retailers to create, schedule and display digital content across screens store-wide, streamlining multimedia content management and enabling real-time updates and targeted messaging to drive awareness, interest and incremental sales. The complete solution comprises all hardware and software needed, and can be deployed, maintained and managed across multiple locations globally. A leading food and beverage chain has deployed this content management service across 100+ stores and achieved substantial cost savings from dynamically managed promotional campaigns, reduced use of paper marketing materials, and reduced manpower needed to manage both campaigns and devices. Lenovo Retail Robotics with Yunji offer

Institute of Molecular and Clinical Ophthalmology Basel Spinout RhyGaze Closes USD 86 Million Series A Round to Further Novel Gene Therapy for Vision Restoration10.1.2025 15:00:00 EET | Press release

RhyGaze, a biotechnology company based in Basel, Switzerland and Philadelphia, Pa., USA, today announced that it has secured a Series A financing of USD 86 million. The round was led by GV (Google Ventures), alongside Arch Venture Partners, F-Prime Capital and founding investors BioGeneration Ventures and Novartis Venture Fund, who contributed USD 11 million to an earlier seed round. RhyGaze was founded on intellectual property exclusively licensed to the company by the Institute of Molecular and Clinical Ophthalmology Basel (IOB), a scientific institute led by Director Botond Roska, M.D., Ph.D., who is a scientific co-founder of RhyGaze. This funding will enable further development of RhyGaze’s lead clinical candidate, a novel gene therapy for optogenetic vision restoration in diseases causing blindness. Activities to be supported include formal pharmacology and toxicology testing, a non-interventional, observational study to assess potential clinical endpoints in patient groups eligi

Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore10.1.2025 14:30:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) with best-in-class potential being studied for the treatment of Immunoglobulin A nephropathy (IgAN) and other B cell-mediated diseases. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250110168811/en/ Under the terms of the agreement, Vertex will receive an upfront payment, as well as certain regulatory milestone payments and tiered royalties, on net sales of pove in the region of focus for Zai Lab. Zai Lab will utilize its extensive research and deve

Compass Pathways Announces Pricing of Underwritten Offering10.1.2025 14:01:00 EET | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the pricing of an underwritten offering of 24,014,728 American Depositary Shares (“ADSs”) and in lieu of ADS, to certain institutional investors, pre-funded warrants to purchase up to 11,044,720 ADSs. Each ADS and pre-funded warrant shall be accompanied by a warrant (“ADS Warrant”) to purchase one ADS, which has an exercise price of $5.796 per ADS, representing a 40% premium to the last sale price and will be exercisable following a specified data milestone. The offering price is $4.275 per ADS and accompanying ADS Warrant, and $4.2649 per pre-funded warrant and accompanying ADS Warrant. All of the securities are to be sold by Compass. The offering is expected to close on or about January 13, 2025, subject to satisfaction of customary closing conditions. The offering was led by Deep Track Capital and included participation

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye